COVID-19 in vaccinated versus unvaccinated hematologic malignancy patients
This article relates to:
-
COVID-19 vaccine effectiveness in patients with hematologic malignancy
- Volume 24Issue 6Transplant Infectious Disease
- First Published online: August 16, 2022
Corresponding Author
Catherine DeVoe
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Correspondence
Catherine DeVoe and Monica Fung, Division of Infectious Diseases, 513 Parnassus Ave Room S-380, University of California San Francisco, San Francisco, CA 94143, USA.
Email: [email protected]; [email protected]
Search for more papers by this authorShraddha Pandey
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorDayana Shariff
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorShagun Arora
Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorTimothy J. Henrich
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Division of Experimental Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorDeborah S. Yokoe
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorCharles R. Langelier
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Chan Zuckerberg Biohub, San Francisco, California, USA
Search for more papers by this authorVenice Servellita
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorCharles Chiu
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorSteve Miller
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorJennifer M. Babik
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorPeter Chin-Hong
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorCorresponding Author
Monica Fung
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Correspondence
Catherine DeVoe and Monica Fung, Division of Infectious Diseases, 513 Parnassus Ave Room S-380, University of California San Francisco, San Francisco, CA 94143, USA.
Email: [email protected]; [email protected]
Search for more papers by this authorCorresponding Author
Catherine DeVoe
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Correspondence
Catherine DeVoe and Monica Fung, Division of Infectious Diseases, 513 Parnassus Ave Room S-380, University of California San Francisco, San Francisco, CA 94143, USA.
Email: [email protected]; [email protected]
Search for more papers by this authorShraddha Pandey
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorDayana Shariff
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorShagun Arora
Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorTimothy J. Henrich
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Division of Experimental Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorDeborah S. Yokoe
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorCharles R. Langelier
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Chan Zuckerberg Biohub, San Francisco, California, USA
Search for more papers by this authorVenice Servellita
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorCharles Chiu
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorSteve Miller
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorJennifer M. Babik
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorPeter Chin-Hong
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorCorresponding Author
Monica Fung
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Correspondence
Catherine DeVoe and Monica Fung, Division of Infectious Diseases, 513 Parnassus Ave Room S-380, University of California San Francisco, San Francisco, CA 94143, USA.
Email: [email protected]; [email protected]
Search for more papers by this authorAbstract
CONFLICT OF INTEREST
CYC is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center and receives research support from Abbott Laboratories, Inc. The other authors declare no potential conflict of interest.
Supporting Information
| Filename | Description |
|---|---|
| tid13835-sup-0001-SuppMat.docx13.7 KB | Table S1. Results of univariate analysis. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020; 136(25): 2881-2892. https://doi.org/10.1182/blood.2020008824.
- 2García-Suárez J, de la Cruz J, Cedillo Á, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol OncolJ Hematol Oncol. 2020; 13(1): 133. https://doi.org/10.1186/s13045-020-00970-7.
- 3Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020; 7(10): e737-e745. https://doi.org/10.1016/S2352-3026(20)30251-9.
- 4Cattaneo C, Daffini R, Pagani C, et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer. 2020; 126(23): 5069-5076. https://doi.org/10.1002/cncr.33160.
- 5Shah GL, DeWolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020; 130(12): 6656-6667. https://doi.org/10.1172/JCI141777.
- 6Wood WA, Neuberg DS, Thompson JC, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020; 4(23): 5966-5975. https://doi.org/10.1182/bloodadvances.2020003170.
- 7Thompson MG, Burgess JL, Naleway AL, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021; 385(4): 320-329. https://doi.org/10.1056/NEJMoa2107058.
- 8 National Comprehensive Cancer Network. NCCN Covid-19 vaccination guidance. Accessed September 21, 2021. https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_70
- 9Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021; 137(23): 3165-3173. https://doi.org/10.1182/blood.2021011568.
- 10Maneikis K, Šablauskas K, Ringelevičiūtė U, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021; 8(8): e583-e592. https://doi.org/10.1016/S2352-3026(21)00169-1.
- 11Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021; 39(8): 1031-1033. https://doi.org/10.1016/j.ccell.2021.07.012.
- 12Peeters M, Verbruggen L, Teuwen L, et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open. 2021; 6(5):100274. https://doi.org/10.1016/j.esmoop.2021.100274.
- 13Di Fusco M, Moran MM, Cane A, et al. Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2. J Med Econ. 2021; 24(1): 1248-1260. https://doi.org/10.1080/13696998.2021.2002063.
- 14Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021; 184(13): 3426-3437. https://doi.org/10.1016/j.cell.2021.04.025.
- 15 World Health Organization. WHO R&D blueprint novel coronavirus COVID-19 therapeutic trial synopsis. Accessed September 10, 2021. https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf
- 16 Centers for Disease Control. CDC covid data tracker. Accessed September 10, 2021. https://covid.cdc.gov/covid-data-tracker/#variant-proportions
- 17Schmidt AL, Labaki C, Hsu CY, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol. 2022; 33(2): 340-346. https://doi.org/10.1016/j.annonc.2021.12.006.
- 18Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19. Blood. 2020; 136(20): 2290-2295. https://doi.org/10.1182/blood.2020008423.
- 19Duléry R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021; 96(8): 934-944. https://doi.org/10.1002/ajh.26209.
- 20Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;( 3)11: E789-E797. https://doi.org/10.1016/S2665-9913(21)00251-4.
- 21Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2020; 22(1): 35-42. https://doi.org/10.1016/S1473-3099(21)00475-8.
